Business Description
Pfizer Inc
NAICS : 325412
SIC : 2834
235 East 42nd Street, New York, NY, USA, 10017
Compare
Compare
Traded in other countries / regions
PFE.Argentina
•
PFE.Austria
•
PFEBC.Belgium
•
PFIZ34.Brazil
•
PFE.Canada
•
PFE.Chile
•
PFE.Germany
•
PFE_KZ.Kazakhstan
•
PFE.Mexico
•
PFE.Peru
•
PFE.Sweden
•
PFE.Switzerland
•
0Q1N.UK
•
PFE.USA
Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.46 | |||||
| Debt-to-EBITDA | 1.04 | |||||
| Interest Coverage | 25.7 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.59 | |||||
| Beneish M-Score | -2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.8 | |||||
| 3-Year EBITDA Growth Rate | 42.9 | |||||
| 3-Year EPS without NRI Growth Rate | 83.1 | |||||
| 3-Year FCF Growth Rate | 31.7 | |||||
| 3-Year Book Growth Rate | 7.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -2.53 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -5.95 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.87 | |||||
| 9-Day RSI | 46.78 | |||||
| 14-Day RSI | 46.62 | |||||
| 6-1 Month Momentum % | 17.91 | |||||
| 12-1 Month Momentum % | 20.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.7 | |||||
| Days Inventory | 89.98 | |||||
| Days Sales Outstanding | 45 | |||||
| Days Payable | 50.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.03 | |||||
| Dividend Payout Ratio | 0.31 | |||||
| 3-Year Dividend Growth Rate | 4.7 | |||||
| Forward Dividend Yield % | 3.22 | |||||
| 5-Year Yield-on-Cost % | 3.96 | |||||
| 3-Year Average Share Buyback Ratio | 0.6 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.23 | |||||
| Operating Margin % | 31.92 | |||||
| Net Margin % | 28.98 | |||||
| ROE % | 37.33 | |||||
| ROA % | 16.11 | |||||
| ROIC % | 18.97 | |||||
| ROC (Joel Greenblatt) % | 228.51 | |||||
| ROCE % | 24.02 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.64 | |||||
| Forward PE Ratio | 7.61 | |||||
| PE Ratio without NRI | 9.59 | |||||
| Shiller PE Ratio | 16.92 | |||||
| Price-to-Owner-Earnings | 9.5 | |||||
| PEG Ratio | 0.92 | |||||
| PS Ratio | 2.8 | |||||
| PB Ratio | 3.16 | |||||
| Price-to-Tangible-Book | 33.4 | |||||
| Price-to-Free-Cash-Flow | 9.94 | |||||
| Price-to-Operating-Cash-Flow | 8.99 | |||||
| EV-to-EBIT | 8.39 | |||||
| EV-to-Forward-EBIT | 6.81 | |||||
| EV-to-EBITDA | 7.3 | |||||
| EV-to-Forward-EBITDA | 6.15 | |||||
| EV-to-Revenue | 2.8 | |||||
| EV-to-Forward-Revenue | 2.85 | |||||
| EV-to-FCF | 9.97 | |||||
| Price-to-Projected-FCF | 1.05 | |||||
| Price-to-Median-PS-Value | 0.7 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.91 | |||||
| Price-to-Graham-Number | 3.77 | |||||
| Earnings Yield (Greenblatt) % | 11.92 | |||||
| Forward Rate of Return (Yacktman) % | 16.73 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 90,940.995 | ||
| EPS (TTM) (€) | 4.61 | ||
| Beta | 0.31 | ||
| Volatility % | 35.16 | ||
| 14-Day RSI | 46.62 | ||
| 14-Day ATR (€) | 0.632087 | ||
| 20-Day SMA (€) | 49.3025 | ||
| 12-1 Month Momentum % | 20.59 | ||
| 52-Week Range (€) | 35.44 - 54.33 | ||
| Shares Outstanding (Mil) | 5,612.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pfizer Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||